Elan Reports Third Quarter 2004 Financial Results

Business Wire, Oct 28, 2004

DUBLIN, Ireland -- Elan Corporation, plc today announced its third quarter 2004 results and provided a business update.

Commenting on Elan's business, Kelly Martin, Elan's president and chief executive officer, said, "All of our energies are focused on delivering our science to patients with unmet medical needs. Today, our emphasis on preparing for a successful launch of Antegren in multiple sclerosis exemplifies our commitment to bringing innovative therapies from the lab to patients around the world."

Commenting on Elan's third quarter results, Shane Cooke, executive vice president and chief financial officer, said, "We continued to report net losses this quarter as we resolve outstanding legacy issues, streamline the balance sheet and, most importantly, invest for a successful launch of Antegren and Prialt. We are optimistic that the dedication, commitment and financial resources we have invested in these products will be reflected in a return to profitability in the 2006 timeframe."